Sun, 22 Nov 2026
02:51:29 pm
Rudransh Sangwan
Published at: November 18, 2026, 11:42 AM
Synopsis
Sun Pharma shares trade at ₹1,871.50, up 6.21% in a month. Read its Q2FY27 revenue, net profit, EBITDA, analyst ratings and technical indicators.

Sun Pharmaceutical Industries shares were trading at ₹1,871.50, up 0.08%, in the latest market snapshot. The stock has gained 6.21% over one month, although it remains down 0.54% over six months.
The pharmaceutical major reported consolidated revenue of ₹16,617 crore in the September 2026 quarter, while net profit stood at ₹1,995 crore, according to the supplied financial data.
| Market Metric | Value |
|---|---|
| Share price | ₹1,871.50 |
| Daily change | +0.08% |
| Market capitalisation | ₹4,48,219.77 crore |
| P/E ratio | 40.80 |
| 52-week high | ₹2,046.90 |
| 52-week low | ₹1,583.70 |
The stock has declined 1.91% in five days, gained 5.91% in one year and delivered a 136.06% return over five years.
Sun Pharma's consolidated revenue increased to ₹16,617 crore in September 2026, from ₹14,875 crore in the September 2025 quarter, representing growth of approximately 11.7%.
However, net profit declined to ₹1,995 crore, compared with ₹3,125 crore a year earlier. EBITDA also decreased to ₹3,894 crore, from ₹4,924 crore in the corresponding quarter.
| Financial Metric | Sep 2025 | Sep 2026 |
|---|---|---|
| Revenue | ₹14,875 crore | ₹16,617 crore |
| EBITDA | ₹4,924 crore | ₹3,894 crore |
| Net profit | ₹3,125 crore | ₹1,995 crore |
| EPS | ₹13.00 | ₹8.30 |
The latest quarter therefore reflects continued revenue growth alongside lower operating earnings and profitability.
Recent company announcements include the availability of its Q2FY27 earnings call recording on October 30 and approval of ESOP 2026 through a postal ballot.
The company also scheduled investor meetings for November 17–18, 2026, according to its November 5 exchange filing.
Sun Pharma's dividend history shows a total dividend of ₹16 per share for FY2026, comprising the amounts listed in the supplied annual dividend data.
According to the supplied data covering 32 analysts, 87.50% have assigned a Buy rating, 3.13% have recommended Hold and 9.38% have a Sell rating.
The stock's RSI stands at 60.46, indicating a neutral reading in the supplied technical data. MACD is bullish at 9.97, while ADX at 35.01 indicates a strong trend. The Ultimate Oscillator, at 41.75, carries a bearish signal.
Investors will be tracking the company's earnings performance, profitability trends and upcoming investor interactions for further updates.
Share price: ₹1,871.50
Daily change: +0.08%
Market capitalisation: ₹4,48,219.77 crore
P/E ratio: 40.80
EPS: ₹47.80
P/B ratio: 5.03
Book value: ₹372.10
Dividend yield: 0.86%
ROE: 13.79%
Debt-to-equity: 0.04
Sector: Healthcare
Industry: Pharmaceuticals & Biotechnology
| Period | Change |
|---|---|
| 1 day | -0.10% |
| 5 days | -1.91% |
| 1 month | +6.21% |
| 6 months | -0.54% |
| 1 year | +5.91% |
| 5 years | +136.06% |
| Metric | Sep 2025 | Jun 2026 | Sep 2026 |
|---|---|---|---|
| Revenue | 14,875 | 15,907 | 16,617 |
| Expenses | 9,951 | 11,086 | 12,724 |
| EBITDA | 4,924 | 4,821 | 3,894 |
| Operating profit margin | 31% | 27% | 21% |
| Depreciation | 730 | 739 | 758 |
| Interest | 100 | 100 | 75 |
| Profit before tax | 4,168 | 4,099 | 3,159 |
| Tax | 1,043 | 1,198 | 1,164 |
| Net profit | 3,125 | 2,901 | 1,995 |
| EPS (₹) | 13.00 | 12.10 | 8.30 |
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Total assets | 92,101 | 1,08,785 |
| Fixed assets | 22,586 | 32,822 |
| Investments | 18,354 | 24,723 |
| Total equity | 72,486 | 83,880 |
| Current liabilities | 18,194 | 22,622 |
| Non-current liabilities | 1,420 | 2,283 |
| Metric | FY2025 | FY2026 |
|---|---|---|
| Operating activities | 14,072 | 12,419 |
| Investing activities | -5,183 | -10,405 |
| Financing activities | -7,906 | -2,513 |
| Net cash flow | 983 | -498 |
| Rating | Share of Analysts |
|---|---|
| Buy | 87.50% |
| Hold | 3.13% |
| Sell | 9.38% |
| Total analysts | 32 |
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 60.46 | Neutral |
| ATR (14) | 42.09 | Less volatile |
| Stochastic (9,6) | 70.28 | Neutral |
| Stochastic RSI (14) | 61.35 | Neutral |
| MACD (12,26) | 9.97 | Bullish |
| ADX (14) | 35.01 | Strong trend |
| Ultimate Oscillator | 41.75 | Bearish |
| ROC | 5.19 | Uptrend and accelerating |
| Williams %R | -33.30 | Neutral |
| Financial Year | Dividend per Share |
|---|---|
| 2022 | ₹10 |
| 2023 | ₹11.50 |
| 2024 | ₹13.50 |
| 2025 | ₹16 |
| 2026 | ₹16 |

Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.

Welspun Living approves ₹3,200 crore capex in subsidiary WHSL, adding Terry Towel, weaving and yarn capacity, with completion targeted for December...

Kirloskar Electric shares trade at ₹104.70 after a 1.8% decline. Check Q2 FY27 results, ₹100 crore working capital facility, financials and technical...

JK Shah Commerce Education shares fell 5% to ₹187.72 and hit the reported lower circuit. Check share price, Q1 FY27 financial data, filings and...

Samyak International reports Q2 FY27 revenue of ₹29 crore and net profit of ₹1 crore. Check its Panda Tech resolution, financial results and stock...

BLS Polymers shares fell 4.33% to ₹270.32 after an 81% rally. Explore FY26 revenue, net profit, EBITDA, Q1 results update, market data and technical...